Which drug is part of the "No Blood, No Drug" REMS program?

Clozapine is part of the "No Blood, No Drug" Risk Evaluation and Mitigation Strategy (REMS) program due to its association with agranulocytosis, a potentially life-threatening decrease in white blood cell count. This risk necessitates close monitoring of patients using the drug, which is indicated for treatment-resistant schizophrenia. As part of the REMS program, patients must have regular blood tests to ensure their white blood cell counts remain within a safe range before continuing to receive clozapine prescriptions. This monitoring is crucial to prevent serious complications and to ensure patient safety while using clozapine.

The other drugs listed do not have this specific REMS requirement related to blood monitoring. Thalidomide has its own REMS concerning fetal exposure due to its teratogenic effects. Alosetron is included in a REMS program primarily focused on its safety for women with severe diarrhea-predominant irritable bowel syndrome, while levonorgestrel does not have any REMS requirements related to blood monitoring or other contraindications that necessitate such rigorous oversight.